Zunzhen Nie, Kaixuan Zeng, Qingguo Yan, Yuangang Liu, Yawei Bian, Jin Zhu, Zhenzhen Guo, Furong He, Hai Shi, Ying Guo
Current treatments for gastric cancer (GC) are suboptimal. Potential therapeutic targets for GC were screened using next-generation sequencing. We examined many mutation genes linked to GC, including TP53 (60%), PIK3CA (19%), LRP1B (13%), and ERBB2 (12%), ARID1A (9%), KMT2C (9%), and KRAS (7%). The KMT2C , KRAS , CDK6, and ARID1A wild-type genes were dominant in diffuse-type GC ( P < .05), but mutations did not influence prognosis. Patients with APC (6%) and CDH1 (8%) wild-type GC presented with vascular invasion ( P < ...
August 7, 2023: International Journal of Surgical Pathology